TEVA241220C17500
- 3.85
- +0.20+5.48%
Teva Pharmaceutical Industries Newsroom
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $28
Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says
U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood
Teva Pharmaceutical Indus Analyst Ratings
FDA Approves Celltrion's Biosimilar of J&J's Stelara
Express News | Teva : BofA Global Research Raises Price Objective to $25 From $23
Daily short sale tracking: NVIDIA's short volume increased by 5 million, with a short sale ratio of 10%
NVIDIA(NVDA.US) ranked top of the list had the largest change in short volume (5.8 million shares), and the short volume ratio of Targa Resources(TRGP.US) reached 46.1%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $28
Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn Into More Strength?
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Why These Two Pharma Stocks Are Surging
J.P. Morgan Maintains Teva Pharmaceutical Industries(TEVA.US) With Hold Rating
Nukkleus, Micron, Teva Pharmaceutical, Quantum Computing, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Teva Pharmaceutical Industries and Sanofi announced that their clinical trial for treating gastrointestinal diseases reached the primary endpoint, with Teva surging over 26% overnight.
Gelonghui, December 18th | Israeli pharmaceutical company Teva Pharmaceutical Industries and Sanofi announced that the latest trial of their jointly developed treatment for inflammatory bowel disease, duvakitug, has reached its primary endpoint. The two companies stated that patients with ulcerative colitis receiving duvakitug had a higher clinical remission rate compared to the placebo group. A group of patients with Crohn's disease treated with duvakitug achieved a higher remission rate than those receiving placebo treatment. Boosted by this news, Teva Pharmaceutical Industries surged over 26% overnight, with an intraday high reaching $21.05, marking a new high since early 2019.
Teva Pharmaceutical Industries Options Spot-On: On December 17th, 341.29K Contracts Were Traded, With 931.03K Open Interest
On December 17th ET, $Teva Pharmaceutical Industries(TEVA.US)$ had active options trading, with a total trading volume of 341.29K options for the day, of which put options accounted for 24.49% of
Unusual Options Activity: WLK, VOD and Others Attract Market Bets, WLK V/OI Ratio Reaches 199.2
EST Dec 17th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
12 Health Care Stocks Moving In Tuesday's Pre-Market Session